Insider Transactions in Q2 2023 at Gemini Therapeutics, Inc. (GMTX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
Brian Richard Mac Donald Chief Innovation Officer |
BUY
Open market or private sale
|
Direct |
600
+4.66%
|
$27,600
$46.76 P/Share
|
|
Jun 30
2023
|
Brian Richard Mac Donald Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
4,324
-13.4%
|
$194,580
$45.15 P/Share
|
|
Jun 29
2023
|
Brian Richard Mac Donald Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
5,100
-6.2%
|
$229,500
$45.9 P/Share
|
|
Jun 28
2023
|
Brian Richard Mac Donald Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
5,100
-6.62%
|
$255,000
$50.14 P/Share
|
|
Jun 28
2023
|
Joanne Bryce Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,072
-46.6%
|
$503,600
$50.34 P/Share
|
|
Jun 28
2023
|
Joanne Bryce Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,880
+41.02%
|
$7,880
$1.01 P/Share
|
|
Jun 28
2023
|
William Jacob Savage Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,384
-7.78%
|
$214,816
$49.97 P/Share
|
|
Jun 28
2023
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,250,000
-53.4%
|
$57,500,000
$46.1 P/Share
|